Evidence map›Paper›PMID 42324362›Full record

ArticleBone marrow transplantation2026

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT.

A Kanellopoulos, M Labopin, A Spyridonidis, E Nikolousis, U Platzbecker, D Blaise, H Sengeloev, F Kinsella, T Schroeder, G Choi and 20 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

A KanellopoulosSheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, United Kingdom. alexandros.kanellopoulos@nhs.net.ORCID http://orcid.org/0000-0002-7400-5416
M LabopinDepartment of Hematology, Hôpital Saint Antoine, Sorbonne University and INSERM UMRs 938, Paris, France.ORCID http://orcid.org/0000-0003-4514-4748
A SpyridonidisBone Marrow Transplantation Unit and Institute of Cellular Therapy, University of Patras, Patras, Greece.ORCID http://orcid.org/0000-0003-3097-2532
E NikolousisHeartlands Hospital, Birmingham, UK.
U PlatzbeckerMedical Clinic and Polyclinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany.ORCID http://orcid.org/0000-0003-1863-3239
D BlaiseProgramme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes-, Marseille, France.
H SengeloevBone Marrow Transplant Unit L 4043, National University Hospital, Copenhagen, Denmark.
F KinsellaBirmingham Centre for Cellular Therapy and Transplantation, Birmingham, UK.
T SchroederDepartment of Bone Marrow Transplantation, University Hospital, Essen, Germany.
G ChoiDepartment of Hematology-Groningen, University Medical Center Groningen (UMCG), Groningen, The Netherlands.
E TholouliClinical Haematology Department, Manchester Royal Infirmary, Manchester, United Kingdom.
P DregerMedizinische Klinik u. Poliklinik V-Heidelberg, University of Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-7429-8570
V PotterDepartment of Haematological Medicine-London, Kings College Hospital, London, United Kingdom.
G SocieDepartment of Hematology - BMT-Paris, Hopital St. Louis, Paris, France.ORCID http://orcid.org/0000-0002-2114-7533
A E C BroersDepartment of Hematology-Rotterdam, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
J PasswegUniversity Hospital, Hematology-Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0001-7092-3351
M EderHannover Medical School, Department of Haematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany.ORCID http://orcid.org/0009-0000-3362-5814
G OlesenAarhus Amtssygehus-Aarhus, Aarhus University Hospital, Aarhus, Denmark.
J H BourhisDepartment of Hematology-Villejuif, Gustave Roussy Cancer Campus, BMT Service, Villejuif, France.
G Van GorkomDepartment Internal Med. Hematology/Oncology-Maastricht, University Hospital Maastricht, Maastricht, The Netherlands.ORCID http://orcid.org/0000-0001-7327-7834
M StelljesDepartment of Hematology/Oncology, University of Muenster, Muenster, Germany.ORCID http://orcid.org/0000-0002-9331-5145
J O BayCHU ESTAING, Service d' hématologie clinique adulte et pédiatrie, Clermont-Ferrand, France.ORCID http://orcid.org/0000-0002-7032-5180
J L ByrneUniversity of Nottingham-Nottingham, Nottingham, United Kingdom.
P CeballosDépartement d'Hématologie Clinique-Montpellier, CHU Lapeyronie, Montpellier, France.
J A SnowdenDivision of Clinical Medicine, School of Medicine and Population Health, The University of Sheffield, Sheffield, UK.ORCID http://orcid.org/0000-0001-6819-3476
Bipin N SavaniVanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-3304-9965
E BrissotDepartment of Hematology, Hôpital Saint Antoine, Sorbonne University and INSERM UMRs 938, Paris, France.ORCID http://orcid.org/0000-0003-4471-418X
F CiceriOspedale San Raffaele s.r.l., Haematology and BMT, Milano, Italy.ORCID http://orcid.org/0000-0003-0873-0123
A NaglerHematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel.
M MohtyDepartment of Hematology, Hôpital Saint Antoine, Sorbonne University and INSERM UMRs 938, Paris, France.ORCID http://orcid.org/0000-0002-7264-808X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The optimal conditioning intensity for allogeneic hematopoietic stem cell transplantation (allo-HCT) in elderly acute myeloid leukemia (AML) remains elusive. We retrospectively analyzed 2900 AML patients aged ≥65 in complete remission who underwent allo-HCT from 2004 to 2021. Conditioning was classified as reduced-intensity conditioning (RIC: fludarabine with busulfan, melphalan, or treosulfan) or non-myeloablative (NMA: fludarabine with total body irradiation). Primary endpoints were overall survival (OS) and leukemia-free survival (LFS); secondary endpoints included non-relapse mortality (NRM), acute and chronic graft-versus-host disease (GVHD), and GVHD/relapse-free survival (GRFS). With follow-up censored to account for differences between arms, OS, LFS, and NRM at 2 years were similar between RIC and NMA on multivariable analysis. Peripheral blood stem cells (PBSC) were independently associated with superior OS (HR 0.67, p = 0.002) and LFS (HR 0.71, p = 0.008) versus bone marrow grafts. GRFS was equivalent between conditioning intensities, although RIC was associated with higher acute GVHD and NMA with higher extensive chronic GVHD. In exploratory analysis, OS and LFS were similar across RIC regimens (Flu/Bu2 as reference: Flu/Mel OS HR 0.91, p = 0.53; Flu/Treo OS HR 0.89, p = 0.42). In older AML patients in remission, RIC and NMA yield comparable survival and NRM; PBSC grafts may be associated with superior outcomes although this warrants validation.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteTransplantation ConditioningAgedBusulfanFemaleGraft vs Host DiseaseHumansMaleRetrospective StudiesTransplantation, HomologousVidarabineBusulfanfludarabineVidarabine

Identifiers

PMID42324362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.